BrosMed Medical Technologies, a Leading Domestic Vascular Intervention Device Maker, Files for IPO

Oct 17, 2023 20:53 CST Updated 20:53

BrosMed Medical

High-end Medical Device Designer, Manufacturer, and Distributor

▍Source: Instrument Family

Recently，Information disclosed on the CSRC's official website shows that BrosMed Medical Co., Ltd.BrosMed MedicalBrosMed Medical Co., Ltd. ("BrosMed Medical") has undergone the filing for IPO tutoring,The tutoring institution is China International Capital Corporation Limited, and the dispatched institution is Guangdong Securities Regulatory Bureau.

It is reported that BrosMed Medical Co., Ltd. was founded in 2012. The company has established nearly ten subsidiaries and offices globally, with its headquarters located in Songshan Lake, Dongguan. It is the largest balloon catheter manufacturer in China.Mainly engaged in the research and production of Class III medical devices for cardiovascular intervention, centered around balloons, catheters, guidewires, and accessories.

According to relevant data statistics, as of May 2023, BrosMed Medical ranks first in the number of registered balloon dilation catheter products among domestically produced enterprises in China.In July 2020, it also completed a C-round financing of several hundred million RMB, with investors including Hillhouse Ventures as the lead investor, Cathay Capital, China Merchants Capital, Northern Light Venture Capital, etc.

The Largest Balloon Catheter Manufacturer in China

BrosMed Medical, established in 2012, is a technology industry-leading medical device platform-type multinational group company that focuses on the research and development, production, and global sales of high-performance transcatheter interventional medical devices and treatment technologies.The core team is one of the earliest teams in China to engage in the development and production of high-end vascular interventional medical devices and is one of the few top coronary balloon catheter technology teams globally.

Global Headquarters Project

The company's headquarters is located in Songshan Lake, Dongguan, with subsidiaries, production bases, research and development centers, and offices established in Dongguan, Shenzhen, Shanghai, Zhuzhou, as well as in the Netherlands, Singapore, India, and other locations in China.

It is worth mentioning that in April 2023, BrosMed Medical's global headquarters project in Songshan Lake officially obtained the planning permit. As early as December 7 last year, the first phase of BrosMed Medical's Songshan Lake global headquarters base project was successfully completed.

It is reported that the project has a total investment of 300 million yuan, with a first-phase land area of 18.27 mu, located at the intersection of Chenxiang Street and Xuelian Street in Songshan Lake. It is planned to become the group's global operation headquarters, mainly engaged in the research and development and production of new high-end medical device products for vascular intervention. The main products include cardiovascular intervention products, peripheral vascular intervention products, neurointervention products, and accessories.

The largest Chinese-produced balloon catheter manufacturing enterprise in China

Currently, BrosMed Medical mainly engages in the research and production of Class III medical devices for cardiovascular interventions, focusing on balloons, catheters, guidewires, and accessories.BrosMed Medical, the largest balloon catheter manufacturer in China, has an annual production capacity of 1.5 million balloon catheters and 3 million technical capacities. The annual production capacity of catheters is 200,000 sets, and the annual production capacity of guidewires is 300,000 sets.The products are sold to thousands of hospitals in more than 60 countries and regions, including China, the United States, Japan, and Europe. "BrosMed" and "BrosMed Medical" have become globally renowned brands for high-quality vascular interventional medical devices.

Hillhouse Investment

Data from Qichacha shows that the company has completed three rounds of financing since its establishment.Including in July 2020, completed a C-round financing of several hundred million RMB.，Led by Hillhouse Ventures, followed by Cathay Capital and Service Trade Fund. The funds from this round of financing will be mainly used for further advancing the company's product R&D, market promotion, and expanded reproduction.

In addition, BrosMed Medical has three subsidiaries: BrosMed Bensun Medical, BrosMed Run Medical, and BrosMed Yuntong Medical, each dedicated to product innovation in different fields.

BrosMed Medical

BrosMed Medical was established on September 3, 2020, and is mainly engaged in the research, development, and sales of active medical devices for prevention, treatment, and rehabilitation.With a research and development center covering an area of over 300 square meters, including technical, information, testing R&D laboratories, and a pilot production workshop.

BrosMed Medical

BrosMed Medical is a manufacturing medical device enterprise specializing in the research and development, production, sales, and service of high-end medical devices.Committed to combining the international product technologies and manufacturing process technologies owned by high-end talent teams with the company's innovative open business model, to achieve a competitive advantage for Chinese brands in the global high-end medical device consumables market. While bringing high returns to the company, it also drives the upgrading and growth of related industrial chains in China.

BrosMed MetaMed

BrosMed MetaMed was established in April 2021 with a registered capital of 5 million yuan, marking a significant strategic layout by BrosMed Medical in the field of neurointervention.Focused on minimally invasive neuro-interventional treatments, committed to creating a one-stop solution for stroke prevention and treatment, with a full product pipeline covering acute ischemic stroke and vascular stenosis treatment, hemorrhagic treatment, and access devices.

BrosMed Medical Ranks First in Balloon Dilation Catheter Product Registrations

As a globally renowned brand for high-quality endovascular interventional medical devices, BrosMed currently owns several globally unique and technologically advanced products. It primarily features four major product families: cardiovascular intervention, peripheral vascular intervention, vascular access, and interventional accessories.

According to relevant data statistics, as of May 2023, there are a total of 101 enterprises in China that have registered medical device products for balloon dilation catheters produced in China. The enterprise with the highest number of registrations is BrosMed Medical Co., Ltd., located in Guangdong Province, with 13 product registrations.

These include the world's smallest CTO balloon – Alveo™ HP Coronary Balloon Dilatation Catheter, the world’s first triple-wire scoring balloon catheter – Tri-Wedge™ Triceratops Peripheral Vascular Scoring Balloon Dilatation Catheter, Yuantong·Changxing Neurointervention Microcatheter (BrosMed Yuantong) Eagle™ Yige Guidewire, and the world’s first POT™ PTCA Proximal and Distal Optimization Technology dedicated balloon, among others.

World's First Tri-Metallic Wire Peripheral Scoring Balloon Catheter

World's First Tri-Metallic Wire Peripheral Scoring Balloon Catheter - Tri-Wedge™ Triceratops Peripheral Vascular Scoring Balloon Dilation Catheter Completed All Enrollment for Clinical Trials in China in May 2021 After Five Years of Innovative Development; In December 2022, two years after its launch in Europe and South America, it received marketing approval from the National Medical Products Administration (NMPA).

It is reported that this product is mainly applicable for dilating lesions within the iliac artery, femoral artery, iliofemoral artery, popliteal artery, infrapopliteal artery, and renal artery. It can also be used to treat obstructive lesions in autologous or artificial arteriovenous dialysis fistulas. Compared with conventional balloons, its unique feature is the three metal scoring wires (triangular in cross-section) evenly distributed on the outer surface of the balloon. When dilating lesions, it creates a stress-concentration effect, enabling the dilation of stubborn stenotic lesions at low pressure. This reduces vascular elastic recoil and residual stenosis caused by insufficient dilation, as well as minimizes flow-limiting dissections resulting from over-dilation. It offers significant advantages for high-resistance lesions and recurrent AVF stenosis, markedly improving the vessel patency rate in patients.

World's First POT™ PTCA Proximal and Distal Optimization Technology Dedicated Balloon

In April 2023, the world's first POT™ PTCA Proximal and Distal Optimization Technology dedicated balloon (BrosMed Medical POT™ PTCA High-Pressure Non-Compliant Balloon Dilation Catheter) received approval from the U.S. Food and Drug Administration (FDA) for market release.It is the world's first dedicated balloon for proximal optimization technique (POT) and distal optimization technique (DOT) used in stent expansion for bifurcation lesions. Prior to this, the POT™ balloon has been深耕 (deeply engaged) in the Chinese and European markets for over a year, accumulating extensive clinical experience.

In addition to conducting business globally with its own brand of balloon catheters, BrosMed Medical can also provide OEM/ODM services to other medical device manufacturers.Providing expertise in the design, development, and production of high-quality balloons, catheters, guidewires, and accessories.

Industry IPO Surge

Vascular interventional technology refers to the minimally invasive treatment technique of introducing specific medical consumables into the lesion area via a vascular route using medical consumables such as puncture needles, guidewires, and catheters under the guidance of medical imaging equipment.According to different treatment areas, vascular interventional devices can be divided into cardiovascular interventional devices (coronary arteries, aorta), cerebrovascular interventional devices, and peripheral vascular interventional devices.

Overall, driven by factors such as an aging population, China's vascular interventional device market remains in a stage of steady growth. In 2021, the market size of China's vascular interventional devices reached 43.2 billion yuan, representing a year-on-year increase of 3.35%. However, over the past two years, the growth rate of China's vascular interventional device market has slowed somewhat. Nevertheless, with changes in the vascular intervention market landscape, the industry's growth drivers are expected to shift from the cardiovascular intervention market to the neurointerventional and peripheral vascular intervention markets. China's vascular interventional device market is anticipated to maintain its growth trend.

With the rapid development of the industry, investment and financing in China's interventional field have become increasingly active in recent years, and related medical device companies have also gradually started to go public through IPOs more frequently.Since 2023, companies such as Hanuy Medical, Beixing Life, Huihe Medical, Saikesaisi Bio, Aike Medical, and Huamai Tech have embarked on their journeys toward IPO.

Hanyu Medical

On March 2, 2023, Shanghai Hydoo Medical Technology Co., Ltd. (hereinafter referred to as "Hydoo Medical") had its STAR Market IPO application accepted. This marks Hydoo Medical's second attempt at an IPO.Plans to raise 1.722 billion yuan, of which 253 million yuan will be used for production base construction projects; 856 million yuan will be used for research and development center construction and registration trial projects; 214 million yuan will be used for marketing network construction projects; and 400 million yuan will be used to supplement working capital.

NorthX Life

On March 30, 2023, Shenzhen NorthX Life Technology Co., Ltd. ("NorthX Life"), a leader in cardiovascular precision interventional solutions, had its STAR Market IPO application accepted.The company plans to raise 1.274 billion yuan for the construction of an interventional medical device industrialization base, interventional medical device research and development projects, marketing network construction projects, and replenishment of working capital. The sponsor institution is CICC.

It is worth mentioning that as early as August 18, 2021, Insight Lifetech Co., Ltd. ("Beixins Life Technology"), filed a prospectus with the Hong Kong Stock Exchange, planning to list on the Main Board of Hong Kong. Goldman Sachs and CICC served as joint sponsors, but there has been no update since then.On October 17, 2022, BrosMed Medical signed an IPO coaching agreement with CICC, planning to list on the STAR Market and abandon Hong Kong for a return to A-share.

Huihe Medical

On March 30, 2023, Huihe Medical and Guotai Junan Securities signed an IPO coaching agreement, officially launching the A-share IPO process.Founded in 2019, Huihe Medical is a cardiovascular interventional platform company dedicated to the research, development, production, and commercialization of cardiovascular interventional medical devices.

As a globally renowned vascular interventional medical device company, BrosMed Medical has been deeply engaged in the interventional industry for over a decade, with a comprehensive industrial layout. Among Chinese manufacturers, it ranks first in the number of registered balloon dilation catheter products and is also the largest producer of balloon catheters in China. In terms of global presence, it has established subsidiaries, production bases, research and development centers, and offices in multiple countries and regions.

The official filing for the listing guidance in Shangshan this time marks the formal start of its IPO journey. Once successfully listed in the future, with the support of capital, the company will also usher in more comprehensive and rapid development.

- END -